View in EDS HTML Full Text PDF Full Text

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.

Saved in:
Bibliographic Details
Title: Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
Authors: Grenfell RFQ; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States., Almeida NBF; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States., Filgueiras PS; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Corsini CA; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Gomes SVC; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., de Miranda DAP; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Lourenço AJ; Hospital da Baleia, Benjamin Guimarães Foundation, Belo Horizonte, Brazil., Martins-Filho OA; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., de Oliveira JG; Laboratório de Imunologia Celular e Molecular, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Teixeira-Carvalho A; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Campos GRF; Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP)São José do Rio Preto, São José do Rio Preto, Brazil., Nogueira ML; Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP)São José do Rio Preto, São José do Rio Preto, Brazil.; Hospital de Base, São José do Rio Preto, Brazil.; Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States., Alves PA; Imunologia de Doenças Virais, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Fernandes GR; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.; Biosystems Informatics, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Castilho LR; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Lima TM; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., de Abreu DPB; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Alvim RGF; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Silva TBS; Imunologia de Doenças Virais, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Jeremias WJ; Laboratório de farmacologia experimental, College of Pharmacy, Universidade Federal de Ouro Preto, Ouro Preto, Brazil., Otta DA; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Campi-Azevedo AC; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.
Corporate Authors: Immunita-001 Team
Source: Frontiers in immunology [Front Immunol] 2022 Jun 09; Vol. 13, pp. 918896. Date of Electronic Publication: 2022 Jun 09 (Print Publication: 2022).
Publication Type: Clinical Trial, Phase IV; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35757764
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Grenfell+RFQ%22">Grenfell RFQ</searchLink>; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States.<br /><searchLink fieldCode="AU" term="%22Almeida+NBF%22">Almeida NBF</searchLink>; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States.<br /><searchLink fieldCode="AU" term="%22Filgueiras+PS%22">Filgueiras PS</searchLink>; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Corsini+CA%22">Corsini CA</searchLink>; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Gomes+SVC%22">Gomes SVC</searchLink>; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22de+Miranda+DAP%22">de Miranda DAP</searchLink>; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Lourenço+AJ%22">Lourenço AJ</searchLink>; Hospital da Baleia, Benjamin Guimarães Foundation, Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Martins-Filho+OA%22">Martins-Filho OA</searchLink>; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22de+Oliveira+JG%22">de Oliveira JG</searchLink>; Laboratório de Imunologia Celular e Molecular, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Teixeira-Carvalho+A%22">Teixeira-Carvalho A</searchLink>; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Campos+GRF%22">Campos GRF</searchLink>; Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP)São José do Rio Preto, São José do Rio Preto, Brazil.<br /><searchLink fieldCode="AU" term="%22Nogueira+ML%22">Nogueira ML</searchLink>; Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP)São José do Rio Preto, São José do Rio Preto, Brazil.; Hospital de Base, São José do Rio Preto, Brazil.; Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Alves+PA%22">Alves PA</searchLink>; Imunologia de Doenças Virais, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Fernandes+GR%22">Fernandes GR</searchLink>; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.; Biosystems Informatics, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Castilho+LR%22">Castilho LR</searchLink>; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Lima+TM%22">Lima TM</searchLink>; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22de+Abreu+DPB%22">de Abreu DPB</searchLink>; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Alvim+RGF%22">Alvim RGF</searchLink>; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Silva+TBS%22">Silva TBS</searchLink>; Imunologia de Doenças Virais, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Jeremias+WJ%22">Jeremias WJ</searchLink>; Laboratório de farmacologia experimental, College of Pharmacy, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.<br /><searchLink fieldCode="AU" term="%22Otta+DA%22">Otta DA</searchLink>; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.<br /><searchLink fieldCode="AU" term="%22Campi-Azevedo+AC%22">Campi-Azevedo AC</searchLink>; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Immunita-001+Team%22">Immunita-001 Team</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2022 Jun 09; Vol. 13, pp. 918896. <i>Date of Electronic Publication: </i>2022 Jun 09 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase IV; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35757764
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2022.918896
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 918896
    Titles:
      – TitleFull: Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Grenfell RFQ
      – PersonEntity:
          Name:
            NameFull: Almeida NBF
      – PersonEntity:
          Name:
            NameFull: Filgueiras PS
      – PersonEntity:
          Name:
            NameFull: Corsini CA
      – PersonEntity:
          Name:
            NameFull: Gomes SVC
      – PersonEntity:
          Name:
            NameFull: de Miranda DAP
      – PersonEntity:
          Name:
            NameFull: Lourenço AJ
      – PersonEntity:
          Name:
            NameFull: Martins-Filho OA
      – PersonEntity:
          Name:
            NameFull: de Oliveira JG
      – PersonEntity:
          Name:
            NameFull: Teixeira-Carvalho A
      – PersonEntity:
          Name:
            NameFull: Campos GRF
      – PersonEntity:
          Name:
            NameFull: Nogueira ML
      – PersonEntity:
          Name:
            NameFull: Alves PA
      – PersonEntity:
          Name:
            NameFull: Fernandes GR
      – PersonEntity:
          Name:
            NameFull: Castilho LR
      – PersonEntity:
          Name:
            NameFull: Lima TM
      – PersonEntity:
          Name:
            NameFull: de Abreu DPB
      – PersonEntity:
          Name:
            NameFull: Alvim RGF
      – PersonEntity:
          Name:
            NameFull: Silva TBS
      – PersonEntity:
          Name:
            NameFull: Jeremias WJ
      – PersonEntity:
          Name:
            NameFull: Otta DA
      – PersonEntity:
          Name:
            NameFull: Campi-Azevedo AC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 06
              Text: 2022 Jun 09
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 13
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1